Andecaliximab
- Generic Name
- Andecaliximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1518996-49-0
- Unique Ingredient Identifier
- 571045EIM4
- Background
Andecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma).
- Associated Conditions
- -
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath